This Workstream was founded in March 2021 and serves as a collaborative platform between industry, academic, regulatory, and patient representatives. Its aim is to strengthen our community’s understanding of pulmonary hypertension due to lung diseases. Every month, the group holds scientific discussions, often featuring focus lectures and journal club sessions. If you’re interested in joining this Workstream, please get in touch.
The Workstream aims to improve the care and daily living of PH group III patients by:
evaluating evidence and epidemiology
defining different phenotypes and endophenotypes
delineating innovative clinical trial design and endpoints
identifying novel diagnostic, digital solutions, and treatment approaches
Consensus statements focusing on ILD-PH published in Pulmonary Circulation
Accepted article: Screening and diagnosis of PH in chronic lung disease, Q4 2024
Continued work in 2024 / 2025
PH Group III is focusing on COPD-PH publications including The Significance of PH in COPD, Pathogenesis and Phenotypes, Management and Treatment combined with Clinical trial design and endpoints.
Our Regional Task Forces don't yet have global coverage. If you're interested in starting one, please contact us.
Interested in accessing global data on PH patient experience? Almost 4,000 patients and carers across 85 countries completed Phase 1 of our PH Global Patient Survey (PH GPS). Questions across all PH groups included diagnostic tests & timelines, genetic testing, treatments, financial burdens, hospital visits, research participation, quality of life, telemedicine, patient-reported outcome measures, and self-monitoring with digital technology. The findings have the potential to improve patient care, guide future research and help us address unmet needs.
